PepGen Inc. ( (PEPG) ) has shared an announcement.
Christopher Ashton, Ph.D., has announced his intention to retire from the Board of Directors of PepGen Inc., effective September 30, 2024, after nearly five years of service, including roles on the Audit and Compensation Committees. His departure will reduce the board size from seven to six members and sees Habib J. Dable joining the Audit Committee. Ashton’s resignation, without any dispute or disagreement, paves the way for a renewed focus on guiding pre-IPO companies. PepGen, a biotech firm dedicated to developing oligonucleotide therapies for severe neuromuscular and neurological diseases, recognized Ashton’s valuable contributions and leadership as it advances its clinical pipeline.
For a thorough assessment of PEPG stock, go to TipRanks’ Stock Analysis page.
